Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07808515 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)

Name: A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) — clinical trial record (NCT07808515)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorRegeneron Pharmaceuticals

Started2026-10-15

View on ClinicalTrials.gov ↗

Regeneron

148 trials monitored

See 16 trials at risk

This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC. The study is looking at: * What side effects cemiplimab, alone or in a combination treatment, might cause * How well cemiplimab, alone or in a combination treatment, works * How cemiplimab, alone or in a combination treatment could affect the immune system, which can help researchers understand why cemiplimab, alone or in a combination treatment, works better in some participants than others

Trial Details

NCT Number	NCT07808515
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Locally Advanced Basal Cell Carcinoma
Enrollment	135 participants
Start Date	2026-10-15
Primary Completion	2030-11-13 (estimated)
Study Completion	2030-11-13 (estimated)
Updated on ClinicalTrials.gov	2026-09-09